# A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy

> **NCT01940887** · PHASE3 · TERMINATED · sponsor: **Ophthotech Corporation** · enrollment: 645 (actual)

## Conditions studied

- Age-Related Macular Degeneration

## Interventions

- **DRUG:** E10030
- **DRUG:** bevacizumab or aflibercept
- **DRUG:** E10030 sham injection

## Key facts

- **NCT ID:** NCT01940887
- **Lead sponsor:** Ophthotech Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-05
- **Primary completion:** 2017-06
- **Final completion:** 2017-09
- **Target enrollment:** 645 (ACTUAL)
- **Last updated:** 2024-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01940887

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01940887, "A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01940887. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*